Your browser doesn't support javascript.
loading
Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology.
Bikdeli, Behnood; McAndrew, Thomas; Crowley, Aaron; Chen, Shmuel; Mehdipoor, Ghazaleh; Redfors, Björn; Liu, Yangbo; Zhang, Zixuan; Liu, Mengdan; Zhang, Yiran; Francese, Dominic P; Erlinge, David; James, Stefan K; Han, Yaling; Li, Yi; Kastrati, Adnan; Schüpke, Stefanie; Stables, Rod H; Shahzad, Adeel; Steg, Philippe Gabriel; Goldstein, Patrick; Frigoli, Enrico; Mehran, Roxana; Valgimigli, Marco; Stone, Gregg W.
Affiliation
  • Bikdeli B; Division of Cardiology, Department of Medicine, NewYork-Presbyterian Hospital/Columbia University Medical Center, New York, New York, United States.
  • McAndrew T; Center for Outcomes Research & Evaluation, Yale School of Medicine, Yale University, New Haven, Connecticut, United States.
  • Crowley A; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, United States.
  • Chen S; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, United States.
  • Mehdipoor G; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, United States.
  • Redfors B; Division of Cardiology, Department of Medicine, NewYork-Presbyterian Hospital/Columbia University Medical Center, New York, New York, United States.
  • Liu Y; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, United States.
  • Zhang Z; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, United States.
  • Liu M; Division of Cardiology, Department of Medicine, NewYork-Presbyterian Hospital/Columbia University Medical Center, New York, New York, United States.
  • Zhang Y; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, United States.
  • Francese DP; Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Erlinge D; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, United States.
  • James SK; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, United States.
  • Han Y; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, United States.
  • Li Y; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, United States.
  • Kastrati A; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, United States.
  • Schüpke S; Department of Cardiology, Lund University, Lund, Sweden.
  • Stables RH; Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden.
  • Shahzad A; Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China.
  • Steg PG; Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China.
  • Goldstein P; Department of Cardiology, Deutsches Herzzentrum München, Technische Universität, Munich, Germany.
  • Frigoli E; Department of Cardiology, Deutsches Herzzentrum München, Technische Universität, Munich, Germany.
  • Mehran R; Liverpool Heart and Chest Hospital, Liverpool, United Kingdom.
  • Valgimigli M; University of Liverpool, Liverpool, United Kingdom.
  • Stone GW; Liverpool Heart and Chest Hospital, Liverpool, United Kingdom.
Thromb Haemost ; 120(2): 348-362, 2020 Feb.
Article in En | MEDLINE | ID: mdl-31820428
ABSTRACT

BACKGROUND:

Individual randomized controlled trials (RCTs) of periprocedural anticoagulation with bivalirudin versus heparin during percutaneous coronary intervention (PCI) have reported conflicting results. Study-level meta-analyses lack granularity to adjust for confounders, explore heterogeneity, or identify subgroups that may particularly benefit or be harmed.

OBJECTIVE:

To overcome these limitations, we sought to develop an individual patient-data pooled database of RCTs comparing bivalirudin versus heparin.

METHODS:

We conducted a systematic review to identify RCTs in which ≥1,000 patients with acute myocardial infarction (AMI) undergoing PCI were randomized to bivalirudin versus heparin.

RESULTS:

From 738 identified studies, 8 RCTs met the prespecified criteria. The principal investigators of each study agreed to provide patient-level data. The data were pooled and checked for accuracy against trial publications, with discrepancies addressed by consulting with the trialists. Consensus-based definitions were created to resolve differing antithrombotic, procedural, and outcome definitions. The project required 3.5 years to complete, and the final database includes 27,409 patients (13,346 randomized to bivalirudin and 14,063 randomized to heparin).

CONCLUSION:

We have created a large individual patient database of bivalirudin versus heparin RCTs in patients with AMI undergoing PCI. This endeavor may help identify the optimal periprocedural anticoagulation regimen for patient groups with different relative risks of adverse ischemic versus bleeding events, including those with ST-segment and non-ST-segment elevation MI, radial versus femoral access, use of a prolonged bivalirudin infusion or glycoprotein inhibitors, and others. Adherence to standardized techniques and rigorous validation processes should increase confidence in the accuracy and robustness of the results.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Peptide Fragments / Heparin / Data Interpretation, Statistical / Percutaneous Coronary Intervention / Anticoagulants / Myocardial Infarction Type of study: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limits: Humans Language: En Journal: Thromb Haemost Year: 2020 Type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Peptide Fragments / Heparin / Data Interpretation, Statistical / Percutaneous Coronary Intervention / Anticoagulants / Myocardial Infarction Type of study: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limits: Humans Language: En Journal: Thromb Haemost Year: 2020 Type: Article Affiliation country: United States